Clinical trial
SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.
NCT00113893 · Scios, Inc., Industry · Completed
Key facts
| NCT number | NCT00113893 |
|---|---|
| Title | SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes. |
| Official title | A Randomized, MultiCenter, Open-Label, Modified Dose-Ascension, Parallel Study of the Safety, Tolerability, and Efficacy of Oral SCIO-469 in Patients With Myelodysplastic Syndromes |
| Lead sponsor | Scios, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bone Marrow Diseases, Myelodysplastic Syndromes, Hematologic Diseases, Bone Marrow Neoplasms |
| Intervention type | Drug |
| Interventions | SCIO-469 |
| Enrollment | 62 |
| Start date | May 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Jun 13, 2005 |
| Last update posted | Nov 7, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: